Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.
J Infect Dis
; 227(11): 1293-1302, 2023 05 29.
Article
en En
| MEDLINE
| ID: mdl-36484484
Respiratory syncytial virus (RSV) is among the main causes of bronchiolitis and pneumonia regularly leading to hospitalization in children. A safe and effective vaccine to prevent RSV infection in this age group has not yet been found, despite great efforts over several decades. This study tested a new candidate RSV vaccine, expressing 3 important pieces of the virus, in toddlers who already had a previous RSV infection. The vaccine was generally well tolerated. Vaccination triggered antibodies against RSV that were able to block the virus in laboratory tests and that persisted for 1 year.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Virus Sincitial Respiratorio Humano
/
Infecciones por Virus Sincitial Respiratorio
/
Vacunas contra Virus Sincitial Respiratorio
Tipo de estudio:
Clinical_trials
Límite:
Humans
/
Infant
Idioma:
En
Revista:
J Infect Dis
Año:
2023
Tipo del documento:
Article
País de afiliación:
España